Flag­ship-backed mi­cro­bio­me com­pa­ny Kalei­do Bio­sciences shuts down

Three months af­ter ini­ti­at­ing lay­offs, hit­ting pause on a planned COPD study and ter­mi­nat­ing an agree­ment with the COPD Foun­da­tion, Kalei­do Bio­sciences is now shut­ting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER